Prognostic Value of Pentraxin-3 Level in Patients with STEMI and Its Relationship with Heart Failure and Markers of Oxidative Stress

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	TOMANDLOVÁ Marie JARKOVSKÝ Jiří TOMANDL Josef KUBKOVA Lenka KALA Petr LITTNEROVÁ Simona GOTTWALDOVÁ Jana KUBENA Petr GANOVSKÁ Eva POLOCZEK Martin ŠPINAR Jindřich MUELLER Christian MEBAZAA Alexandre PÁVKOVÁ GOLDBERGOVÁ Monika PAŘENICA Jiří
Year of publication	2015
Type	Article in Periodical
Magazine / Source	Disease Markers
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.1155/2015/159051
Field	Cardiovascular diseases incl. cardiosurgery
Keywords	ACUTE MYOCARDIAL-INFARCTION; C-REACTIVE PROTEIN; ACUTE CORONARY SYNDROME; PERFORMANCE LIQUID-CHROMATOGRAPHY; LONG PENTRAXIN; ANTIOXIDANT ACTIVITY; RISK-ASSESSMENT; TNF-ALPHA; ELEVATION; PTX3
Description	Objective. Pentraxin-3 (PTX3) appears to have a cardioprotective effect through a positive influence against postreperfusion damage. This study assesses the prognostic value of PTX3 level and its relationship with clinical parameters and markers of oxidative stress and nitric oxide metabolism in patients with ST-elevation myocardial infarction (STEMI). Methods. Plasma/serum levels of several biomarkers of inflammation and oxidative stress and nitrite/nitrate were assessed upon admission and 24 h after STEMI onset in patients treated by primary percutaneous coronary intervention. Results. ROC analysis showed that plasma PTX3 at 24 h was a strong predictor of 30-day and 1-year mortality and independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year. The inflammatory response expressed by PTX3 had a significant relationship with age, heart failure, infarct size, impaired flow in the infarct-related artery, and renal function and positively correlated with neopterin, TNF-alpha, 8-hydroxy-2'-deoxyguanosine, and nitrite/nitrate. Conclusions. Plasma PTX3 at 24 h after STEMI onset is a strong predictor of 30-day and 1-year mortality. PTX3 as a single biomarker is comparable with currently used scoring systems (TIMI or GRACE) or B-type natriuretic peptide. PTX3 is also an independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year.
Related projects:	Příspěvek chemických a biochemických metodik ke studiu molekulární podstaty vybraných patologických stavů a onemocnění Diagnostika akutní myokarditidy mimikující akutní infarkt myokardu s ST elevacemi